Zim Laboratories Ltd Q2 FY2024 Concall Summary

Key Takeaways

• Sharp QoQ recovery, operating leverage visible: Total operating income rebounded 27% QoQ as external disruptions eased, lifting EBITDA margin to 12.5% and demonstrating the steep operating leverage once revenue crosses a threshold.
• New platforms are graduating from pipeline to P&L: NIP and OTF revenue grew over 50% QoQ and together reached 13% of total revenue, with the first OTF commercial supply shipped to Europe and a first-time disclosure of segment sales in the investor presentation.
• Regulated-market pivot is underway but early: Three EU dossier submissions are complete, three more due in H2, and a Canadian partner received marketing authorization on Zim's dossier, but management explicitly ties material revenue translation to the second half of FY25.
• Guidance is anchored to last year, not the new pipeline: Management expects to repeat last year's revenue performance for FY24 and declined to give any FY25 numbers, calling it "too early" while the company is in transition.
• What to watch next quarter: Whether the NIP/OTF revenue share continues its sequential climb, any update on the Suboxone bioequivalence timeline (currently partner-dependent), and the pace of Nutra stabilization across the next 2–3 quarters.

Revenue Recovery & Operating Leverage

• Q1 to Q2 swing: Total operating income grew 27% QoQ after a weak Q1 hit by external problems; pharmaceutical business grew 37% QoQ to ₹74 crore, contributing 86% of total operating income.
• Export-led rebound: Export revenue grew 25.8% QoQ and now makes up 79% of total operating income, with Asia and India contributing a higher share versus prior quarters and steady growth from EU, LATAM and other regulated/Pharmerging markets reaching 7% of total revenue.
• Operating leverage mechanics: Management pointed to the Q1-to-Q2 difference as evidence that once revenue crosses a certain level (around ₹100 cr), a significant operating leverage effect kicks in, driven by volume and product mix.
• Finance cost tailwind: Finance cost declined 30% QoQ to ₹1.2 crore, providing an additional lift to the bottom line.
• Margin dynamics by market: Moving from Rest of World to emerging markets to regulated markets generally improves margins, and the geographical mix shift underway supports the margin outlook.

Dr. Anwar Daud: "As you can see the difference between the Quarter 1 and Quarter 2, there is a very interesting operating leverage we have the moment it starts going above a certain number. All the numbers and volume."

NIP & OTF: The New Growth Engine

• First-time segment disclosure: NIP and OTF sales were disclosed for the first time in the investor presentation, signaling management's view that these are now material, reportable lines. NIP revenue grew 53.6% QoQ, OTF revenue grew 62.6% QoQ, and together they reached ₹10.9 crore or 13% of total revenue.
• Regulatory milestones stacking up: One NIP dossier was filed in the EU (third cumulative), the first OTF commercial supply (sildenafil citrate 50 mg ODS) shipped to Europe, and a Canadian partner received marketing authorization for an antiemetic OTF product using Zim's dossier. Marketing partners also submitted 8 OTF registrations in Pharmerging and RoW markets.
• Dossier pipeline: 12 finished formulation dossiers and 9 NIP dossiers were submitted during the quarter; three submissions are complete and three more are due in H2, all currently under review.
• Sassa launch underway: The first supply of Sassa has taken place in Europe, with two orders accepted from one partner and the product registered with a second partner using Zim's dossier.
• Revenue translation timeline: Management projects material business translation from these filings in the second half of FY25, with an overall increase expected in the coming quarters of this financial year and next, both in absolute terms and as a percentage of total business.
• Regulated market cadence: The 210-day regulatory procedure (extendable to one year) is expected to complete by end of FY24, after which a significant difference in most NIP products should become visible in the second half of FY25 as volumes build following initial marketing authorizations.

Dr. Anwar Daud: "Just now, as you can see, the filings in the regulated markets are taking place, and more and more of the translation into business from these filings will be as we have projected in the second half of 25."

Nutraceutical Stabilization

• Order book improving: The Nutra business is stabilizing with a steady increase in order position, and the currency crisis in the MENA region appears to be easing.
• Geographic derisking: Growth is being cultivated in India, Asia and Southeast Asia to reduce concentration risk, and margins are improving as the business mix shifts from RoW toward emerging and regulated markets.
• Normalization timeline: Management expects the next 2–3 quarters to show normalization, though it cautioned there is no certainty on the exact pace.

Business Model & Cost Structure

• Asset-light commercial model: The company has no sales force or feet on the street; a business development team builds long-lasting relationships with local partners who are strong in their markets. Supply agreements are long-term and there is no technology transfer to other plants.
• IP-led, not contract manufacturing: Zim does not do job work or contract manufacturing; it leverages its own IP with transfer prices that include profit and a premium, and the supply chain for PFI and formulations is undifferentiated with APIs sourced from at least two approved vendors.
• API cost protection: API price volatility is modulated through long-term supply contracts with two sources per API, protecting margins from commodity swings; margins tend to increase slightly over time as volumes improve.
• Top-10 concentration: Per an analyst's math, the top 10 molecules contribute approximately 57% of revenue.

Dr. Anwar Daud: "We do not have feet on the street. We do not have a sales force in the market. We have a business development team who actually build long-lasting relationships with different partners who are strong in their local market."

Pipeline: Suboxone & Co-Development

• Suboxone status: The chemical development phase is complete and the company is waiting on its co-development partner to finalize the bioequivalence protocol, study center and related logistics. Management hopes preliminary work concludes by December or by March, but stressed the decision sits with the partner and is not within Zim's control.
• Pipeline disclosure policy: Management declined to disclose upcoming products expected in the next quarter or two, stating "we normally do not disclose this" and "I am not at liberty to discuss."

Dr. Anwar Daud: "Because it is in the court of the partner because the partner has to finalize the bioequivalence protocol, the study center, and all those things. I hope we will be able to conclude the preliminary work that needs to be done because the bioequivalence has begun by December. But it not a now decision to make then the partner involved in it, hopefully by December or by March, we should have the bioequivalence."

Margin & Return Profile

• Q2 margin snapshot: EBITDA margin improved to 12.5% and PAT margin to 4.8%, both recovering from a depressed Q1 base as operating leverage took hold.
• H2 outlook: Management is optimistic about H2 and expects sequential margin improvement driven by operating leverage, with the absolute margin number remaining the same or improving and the trend staying positive.
• Mix shift tailwind: As NIP and OTF products gain traction in regulated and emerging markets, they are expected to contribute positively to overall margins, reinforcing the operating leverage story.

Guidance & Commitments

Key Metrics